Skip to content
Clinical Trials – home

Reumatop Grzegorz Rozumek Karin Pistorius Sp. j.

Verified siteinfoFast reply

Poland Ul. Pigwowa 4 A, 52-210 Wroclaw, Poland

  • 4 trials recruiting
  • Systemic lupus erythematosus · Dry eye · Sjogren's syndrome
  • Adults and children

About Specializations

Reumatop Grzegorz Rozumek Karin Pistorius Sp. j. in Wroclaw, Poland specialises in clinical trials of conditions such as Systemic lupus erythematosus, Dry eye, Sjogren's syndrome, Axial spondyloarthritis, and other specialisations. This site conducts important research.

Main research areas of the site

Musculoskeletal and Autoimmune Inflammation

At Reumatop Grzegorz Rozumek Karin Pistorius Sp. j. in Wroclaw, clinical research in rheumatology focuses on musculoskeletal diseases and immune system diseases, especially conditions driven by chronic inflammation.

  • Studies in psoriatic arthritis, axial spondyloarthritis, and rheumatoid arthritis
  • Research aimed at comparing new therapies with placebo to better control disease activity
  • Trials designed to evaluate whether treatments can improve symptoms and support remission in inflammatory joint disease

These studies are helping assess the effectiveness and safety of emerging treatment options for people living with persistent joint pain, stiffness, and immune-mediated inflammation.

Systemic Autoimmune Diseases

This site is also involved in research on complex autoimmune disorders such as systemic lupus erythematosus and Sjögren’s syndrome, with a strong emphasis on understanding how to better control widespread immune activity.

  • Trials in SLE focused on improving disease control and measuring responder outcomes
  • Research in Sjögren’s syndrome aimed at long-term safety, tolerability, and symptom management
  • Comparative studies testing whether new therapies perform better than placebo in reducing autoimmune disease burden

The main goal is to identify treatments that may offer more durable benefit for patients with difficult-to-manage systemic immune diseases.

Digestive and Immune-Mediated Disease Research

Clinical trials at this hospital/clinic also extend to digestive system diseases, particularly Crohn’s disease, reflecting interest in immune-driven inflammation beyond the joints.

  • Research evaluating long-term effectiveness of newer therapies in Crohn’s disease
  • Studies focused on maintaining disease control and monitoring safety over time
  • Work that supports better treatment strategies for chronic inflammatory bowel disease

Overall, the research portfolio combines gastroenterology and immunology to improve care for patients with persistent inflammatory conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Pigwowa 4 A52-210 WroclawPoland
Recruiting now
4 trials
Conditions studied
9
Partner status
Verified site

More sites in WroclawPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on Tofacitinib for Patients with Early Active Axial Spondyloarthritis Who Did Not Respond to NSAIDs

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Naproxen
  • Sponsor:Charite Universitaetsmedizin Berlin KöR
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.